Rchr
J-GLOBAL ID:201101085132854710   Update date: Mar. 29, 2020

Hayakawa Fumihiko

ハヤカワ フミヒコ | Hayakawa Fumihiko
Affiliation and department:
Job title: Professor
Research field  (1): Pharmaceuticals - chemistry and drug development
Research keywords  (7): Drug screening ,  Genetic analysis ,  Pathophysiological analysis ,  Multi-agent clinical trial ,  Clinical trial ,  Malignant lymphoma ,  Leukemia
Papers (52):
  • Sakamoto A, Kunou S, Shimada K, Tsunoda M, Aoki T, Iriyama C, Tomita A, Nakamura S, Hayakawa F, Kiyoi H. Pyruvate secreted from patient-derived cancer-associated fibroblasts supports survival of primary lymphoma cells. Cancer science. 2018
  • Tanaka Y, Kawazu M, Yasuda T, Tamura M, Hayakawa F, Kojima S, Ueno T, Kiyoi H, Naoe T, Mano H. Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia. Haematologica. 2018. 103. 11. e522-e526
  • Shimada K, Hayakawa F, Kiyoi H. Biology and management of primary effusion lymphoma. Blood. 2018. 132. 18. 1879-1888
  • Hatta Yoshihiro, Mizuta Shuichi, Matsuo Keitaro, Ohtake Shigeki, Iwanaga Masako, Sugiura Isamu, Doki Noriko, Kanamori Heiwa, Ueda Yasunori, Yoshida Chikamasa, Dobashi Nobuaki, Maeda Tomoya, Yujiri Toshiaki, Monma Fumihiko, Ito Yoshikazu, Hayakawa Fumihiko, Takeuchi Jin, Kiyoi Hitoshi, Miyazaki Yasushi, Naoe Tomoki. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph plus ALL. ANNALS OF HEMATOLOGY. 2018. 97. 9. 1535-1545
  • Inoue C, Sobue S, Aoyama Y, Mizutani N, Kawamoto Y, Nishizawa Y, Ichihara M, Abe A, Hayakawa F, Suzuki M, Nozawa Y, Murate T. BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells. Biochemistry and biophysics reports. 2018. 15. 69-75
more...
MISC (52):
  • Sakamoto A, Kunou S, Shimada K, Tsunoda M, Aoki T, Iriyama C, Tomita A, Nakamura S, Hayakawa F, Kiyoi H. Pyruvate secreted from patient-derived cancer-associated fibroblasts supports survival of primary lymphoma cells. Cancer science. 2018
  • Tanaka Y, Kawazu M, Yasuda T, Tamura M, Hayakawa F, Kojima S, Ueno T, Kiyoi H, Naoe T, Mano H. Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia. Haematologica. 2018. 103. 11. e522-e526
  • Shimada K, Hayakawa F, Kiyoi H. Biology and management of primary effusion lymphoma. Blood. 2018. 132. 18. 1879-1888
  • Hatta Yoshihiro, Mizuta Shuichi, Matsuo Keitaro, Ohtake Shigeki, Iwanaga Masako, Sugiura Isamu, Doki Noriko, Kanamori Heiwa, Ueda Yasunori, Yoshida Chikamasa, Dobashi Nobuaki, Maeda Tomoya, Yujiri Toshiaki, Monma Fumihiko, Ito Yoshikazu, Hayakawa Fumihiko, Takeuchi Jin, Kiyoi Hitoshi, Miyazaki Yasushi, Naoe Tomoki. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph plus ALL. ANNALS OF HEMATOLOGY. 2018. 97. 9. 1535-1545
  • Inoue C, Sobue S, Aoyama Y, Mizutani N, Kawamoto Y, Nishizawa Y, Ichihara M, Abe A, Hayakawa F, Suzuki M, Nozawa Y, Murate T. BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells. Biochemistry and biophysics reports. 2018. 15. 69-75
more...
Lectures and oral presentations  (4):
  • Treatment of acute lymphoblastic leukemia in adolescent and young adult by pediatric protocols.
    (2016)
  • New molecular targets of B-cell acute lymphoblastic leukemia
    (2016)
  • Genetic abnormalities of AYA ALL and its treatment strategy by pediatric like protocols.
    (2016)
  • Development of growth signal inhibitors for hematopoietic malignancies
    (2011)
Education (1):
  • 1987 - 1993 Nagoya University Faculty of Medicine
Work history (9):
  • 2018/04/01 - 現在 Nagoya University
  • 2018/04/01 - 現在 Nagoya University Professor
  • 2016/05/01 - 現在 Nagoya University
  • 2015/05/01 - 2018/03/31 Nagoya University Lecturer
  • 2010/04/01 - 2016/04/30 Nagoya University
Show all
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page